# Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN

> **NCT03529422** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 18 (actual)

## Conditions studied

- Larynx
- Lip
- Oral Cancer
- Digestive Organs--Diseases

## Interventions

- **DRUG:** Durvalumab
- **RADIATION:** Intensity Modulated Radiotherapy Treatments

## Key facts

- **NCT ID:** NCT03529422
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-07
- **Primary completion:** 2024-07-01
- **Final completion:** 2026-05-06
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03529422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03529422, "Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT03529422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*